Comparative Pharmacology
Head-to-head clinical analysis: EPANOVA versus PROCALAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPANOVA versus PROCALAMINE.
EPANOVA vs PROCALAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
Procalamine is a combination of antihistamines (chlorpheniramine and pheniramine) and a sympathomimetic (phenylephrine). Chlorpheniramine and pheniramine are histamine H1 receptor antagonists, blocking the effects of histamine, while phenylephrine is an alpha-1 adrenergic receptor agonist causing vasoconstriction.
4 g orally once daily as 4 capsules of 1 g each with food.
Intravenous: 1.5 g/kg ideal body weight (IBW) over 12-24 hours; maximal rate: 0.625 g/kg/hour.
None Documented
None Documented
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
2.5–3.5 hours in healthy adults; prolonged in renal impairment (up to 20–30 hours in ESRD).
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Primarily renal; >95% of the dose excreted unchanged in urine within 24 hours. Minimal biliary/fecal elimination (<5%).
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution